EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease

Yoshiko Furiya, Takami Tomiyama, Tesseki Izumi, Naoki Ohba, Satoshi Ueno

Dementia and Geriatric Cognitive Disorders Extra · 13.03.2018 · 8 (1) · 77-84

DOI: 10.1159/000487358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders Extra, online erschienen am 13.03.2018. Verfasst von Yoshiko Furiya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nara Medical University, Kashihara, Japan. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Weight loss accelerates cognitive decline and increases mortality in patients with dementia. While acetylcholinesterase (AChE) inhibitors are known to cause appetite loss, we sometimes encounter patients in whom switching from donepezil (AChE inhibitor) to rivastigmine (AChE and butyrylcholinesterase [BuChE] inhibitor) improves appetite. Since BuChE inactivates ghrelin, a potent orexigenic hormone, we speculated that rivastigmine improves appetite by inhibiting BuChE-mediated ghrelin inactivation.

Methods

The subjects were patients with mild to moderate Alzheimer disease treated with either rivastigmine patch (n = 11) or donepezil (n = 11) for 6 months. Before and after treatment, we evaluated appetite (0, decreased; 1, slightly decreased; 2, normal; 3, slightly increased; 4, increased), cognitive function, and blood biochemical variables, including various hormones.

Results

Rivastigmine treatment significantly improved appetite (from 1.6 ± 0.5 to 2.6 ± 0.7), whereas donepezil treatment did not (from 2.0 ± 0.0 to 1.8 ± 0.4). Simultaneously, rivastigmine, but not donepezil, significantly decreased the serum cholinesterase activity (from 304.3 ± 60.5 to 246.8 ± 78.5 IU/L) and increased the cortisol level (from 11.86 ± 3.12 to 14.61 ± 3.29 μg/dL) and the acyl/des-acyl ghrelin ratio (from 4.03 ± 2.96 to 5.28 ± 2.72). The levels of leptin, insulin, total ghrel­in, and cognitive function were not significantly affected by either treatment.

Conclusions

Our results suggest that compared with donepezil, rivastigmine has the advantage of improving appetite by increasing the acyl/des-acyl ghrelin ratio and cortisol level, thereby preventing weight loss.

Schlagwörter

Stichwörter der Autor:innen

Acyl/des-acyl ghrelin ratioAlzheimer diseaseAppetiteCortisolGhrelinHigh-density lipoprotein cholesterolRivastigmine

Autor:innen und Institutionen

  • Department of Neurology, Nara Medical University, Kashihara, Japan.
  • Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, Osaka, Japan.
  • Department of Neurology, Heisei Memorial Hospital, Kashihara, Japan.

Zitieren

APA

Furiya, Y., Tomiyama, T., Izumi, T., Ohba, N., & Ueno, S. (2018). Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra, 8(1), 77-84. https://doi.org/10.1159/000487358

Vancouver

Furiya Y, Tomiyama T, Izumi T, Ohba N, Ueno S. Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra. 2018;8(1):77-84. doi:10.1159/000487358

BibTeX
@article{Furiya2018,
  author = {Furiya, Yoshiko and Tomiyama, Takami and Izumi, Tesseki and Ohba, Naoki and Ueno, Satoshi},
  title = {Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease},
  journal = {Dementia and Geriatric Cognitive Disorders Extra},
  year = {2018},
  volume = {8},
  number = {1},
  pages = {77--84},
  doi = {10.1159/000487358}
}
Kostenlos starten →